Product Description: Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies[1][2][3][4][5][6][7].
Applications: Cancer-programmed cell death
Formula: C6404H9908N1724O2004S50
References: [1]1.Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82. /[2]2.Kendler DL, et al. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74. /[3]3.Dell'Aquila E, et al. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020 Nov;20(11):1261-1274. /[4]4.Mosch A, et al. Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. Arch Oral Biol. 2019 May;101:23-29./[5]5.Shangguan L, et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen Ther. 2024 Mar 26;27:181-190. /[6]6.Kondegowda NG, et al. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metab. 2015 Jul 7;22(1):77-85. /[7]7.Andreassen CH, et al. Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity. Cell Rep Med. 2024 Oct 15;5(10):101783.
CAS Number: 615258-40-7
Molecular Weight: 144716.86
Compound Purity: 99.10
Research Area: Cancer; Endocrinology
Solubility: H2O
Target: Apoptosis;Caspase;NF-κB;RANKL/RANK
English
Deutsch
